Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
CRISPR Therapeutics AG - Common Shares
(NQ:
CRSP
)
55.08
-1.63 (-2.87%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 26, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about CRISPR Therapeutics AG - Common Shares
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
34
35
Next >
3 Stocks With Huge Catalysts on the Way
↗
April 22, 2023
Big news could mean big boosts for these stocks.
Via
The Motley Fool
2 Growth Stocks That Could Keep Growing for Decades
↗
April 21, 2023
These businesses will likely only get larger in the future.
Via
The Motley Fool
Better Big Biotech Buy: Biogen vs. Vertex
↗
April 20, 2023
One is slightly cheaper than the other.
Via
The Motley Fool
The Top 3 Biotech Stocks to Watch in 2023
↗
April 20, 2023
Investors would be wise to keep an eye on the biotech boom, and these top biotech stocks to watch as we get deeper into 2023.
Via
InvestorPlace
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
↗
April 20, 2023
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is...
Via
Benzinga
Why CRISPR Therapeutics Stock Is Marching Higher Today
↗
April 17, 2023
This gene-editing stock has been heating up over the past week.
Via
The Motley Fool
What 14 Analyst Ratings Have To Say About CRISPR Therapeutics
↗
April 17, 2023
Via
Benzinga
Is CRISPR Therapeutics Stock a Buy Now?
↗
April 14, 2023
The biotech could soon be a commercial-stage company.
Via
The Motley Fool
CRISPR Therapeutics Is an Interesting 'Gene Editing Play for 2023' With Significant Upside, Says Analyst
↗
April 13, 2023
Via
Benzinga
3 High-Growth Biotech Stocks Poised for Success in 2023
↗
April 18, 2023
If you look for growth opportunities wherever you can find them, there are some high-growth biotech stocks that could present an opportunity
Via
InvestorPlace
The Top Healthcare Stocks to Buy With $100
↗
April 18, 2023
A small investment now may bring big results over time.
Via
The Motley Fool
Why Shares of Editas Medicine Rose Monday
↗
April 17, 2023
The company is benefiting from positive news affecting other gene-editing stocks.
Via
The Motley Fool
Better Growth Stock: Axsome vs. CRISPR Therapeutics
↗
April 16, 2023
These companies are both in the early days of their growth stories.
Via
The Motley Fool
Cathie Wood Just Bought More CRISPR Therapeutics (CRSP) Stock
↗
April 13, 2023
Shares of CRSP stock are moving higher following an initiation of coverage by Cantor Fitzgerald and continued buys from Cathie Wood.
Via
InvestorPlace
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
↗
April 13, 2023
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks.
Via
InvestorPlace
Why Shares of CRISPR Therapeutics Jumped Thursday
↗
April 13, 2023
An independent drug-pricing group said that a $1.9 million cost for the company's exa-cel therapy would be cost-effective.
Via
The Motley Fool
Where Will CRISPR Therapeutics Be in 5 Years?
↗
April 09, 2023
Could CRISPR Therapeutics be the next big healthcare stock?
Via
The Motley Fool
CRISPR Stock: Bull vs. Bear
↗
April 08, 2023
CRISPR's first approved product may be right around the corner.
Via
The Motley Fool
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
↗
April 13, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
↗
April 13, 2023
Via
Benzinga
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
↗
April 13, 2023
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
2 Nasdaq Growth Stocks That Are Screaming Buys in April
↗
April 13, 2023
Massive drivers of fresh earnings are drawing closer, and risks are declining.
Via
The Motley Fool
These Up-and-Coming Stocks Are Screaming Buys Right Now
↗
April 13, 2023
Both companies could deliver revenue and share price growth over the long term.
Via
The Motley Fool
Could This Move Make Vertex's Next Blockbuster Even Bigger?
↗
April 12, 2023
Vertex is showing it can branch out beyond its cystic fibrosis specialty.
Via
The Motley Fool
Cryoport Supports Clinical Trials And Commercial Therapies Across The High-Growth BioTech Industry: Is Its Current Stock Price An Opportunity?
↗
April 10, 2023
The global biotechnology industry was worth $859 billion in 2022, and it is predicted to reach $1.6 trillion by 2030, growing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.
Via
Benzinga
5 S&P 500 Stocks Showing Strength As Recession Fears Rise
↗
April 07, 2023
Medical stocks are holding up amid economic and market uncertainty.
Via
Investor's Business Daily
What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio
↗
April 06, 2023
Both biotechs are aiming for the same markets, but they are not equally risky.
Via
The Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
↗
April 06, 2023
Neither stock is a good choice for those who can't handle a lot of risk.
Via
The Motley Fool
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
↗
April 06, 2023
Via
Benzinga
2 Under-the-Radar Biotech Stocks to Buy in 2023
↗
April 05, 2023
Both companies have game-changing product portfolios that should result in stock price growth.
Via
The Motley Fool
< Previous
1
2
...
19
20
21
22
23
24
25
26
27
...
34
35
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.